Dull, lackluster hair? The best hair gloss treatments can restore shine in minutes, all from the comfort of your home.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

We're one step closer to not just treating baldness but preventing it, with scientists making an important discovery that ...

Finding a hair-loss fix has required ongoing research and trials. As UCLA scientists target a promising treatment option, ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the ...

The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...

Hair transplant procedure (including consultation, local anesthetic, explantation, implantation, and post-procedure PRP): ...

Within six months, former US Army sergeant Mark Millich began experiencing dizziness, fatigue, cold sweats and was slurring his words - which he described it as feeling 'lobotomized'.

Citing third-party data, Hettenback said downloads of the Hims & Hers apps increased 47% year over year in February. What it means for Hims & Hers stock. On Apple's App Store, Him ...

The young man, aged 26, started taking drugs prescribed to him to halt his progressing hair loss but what followed were ...